Van Laake

Nov 5, 2024 | link.springer.com | Van Den Hout |Gerardus P. J |Van Laake

Dear Editor,With great interest we read the systematic review by Wiethoff et al. regarding the cost-effectiveness of therapies for inherited cardiomyopathies [1]. Left ventricular assist devices (LVADs) have demonstrated a significant survival benefit in patients with end stage heart failure (HF). To our surprise, the infographic (Fig. 1) in their review suggests that LVADs are not cost-effective in patients with dilated cardiomyopathy.

May 6, 2024 | link.springer.com | Van Laake |van der Harst |van der Meer |De Waal

AbstractIn refractory cardiogenic shock, temporary mechanical support (tMCS) may be crucial for maintaining tissue perfusion and oxygen delivery. tMCS can serve as a bridge-to-decision to assess eligibility for left ventricular assist device (LVAD) implantation or heart transplantation, or as a bridge-to-recovery. ECPELLA is a novel tMCS configuration combining venoarterial extracorporeal membrane oxygenation with Impella.